Reuters logo
BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr
May 22, 2017 / 9:56 PM / 4 months ago

BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr

May 22 (Reuters) - Sanofi Sa

* Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients

* Regeneron pharmaceuticals inc - in u.s., kevzara will be marketed by regeneron and sanofi genzyme, specialty care global business unit of sanofi

* Regeneron pharmaceuticals, inc says in clinical trial program, sarilumab was statistically significant

* Regeneron - final decision on marketing authorization application for kevzara in european union will be made by european commission in coming months

* Regeneron pharmaceuticals inc - u.s. Wholesale acquisition cost of kevzara is $39,000/year for 200 mg and 150 mg doses Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below